Confirmation of Board appointments

Tissue Regenix Group plc

Confirmation of Board appointments

Leeds, 5 January 2021 - Tissue Regenix Group (AIM:TRX) ("Tissue Regenix" or the "Group") the regenerative medical devices company, announces that, following the Group's announcement on 4 December 2020, Brian Phillips and Trevor Phillips have been appointed to the Board as independent Non-Executive Directors of Tissue Regenix.

Brian Phillips is now Chair of the Audit Committee and Trevor Phillips is Chair of the Remuneration Committee. 

For more Information:

About Tissue Regenix

Tissue Regenix is a leading medical devices company in the field of regenerative medicine. The company's patented decellularisation ('dCELL®') technology removes DNA and other cellular material from animal and human soft tissue leaving an acellular tissue scaffold which is not rejected by the patient's body and can then be used to repair diseased or worn out body parts. Current applications address many critical clinical needs such as sports medicine, heart valve replacement and wound care.

In August 2017 Tissue Regenix acquired CellRight Technologies®, a biotech company that specializes in regenerative medicine and is dedicated to the development of innovative osteoinductive and wound care scaffolds that enhance healing opportunities of defects created by trauma and disease. CellRight's human osteobiologics may be used in spine, trauma, general orthopaedic, foot & ankle, dental, and sports medicine surgical procedures.

Regulatory disclosures

Trevor Michael Phillips, 59, has been a director or partner of the following companies or partnerships during the past five years:

Trevor holds no shares in Tissue Regenix plc and there are no further disclosures required in accordance with AIM Rule 17 and Schedule Two paragraph (g) of the AIM Rules for Companies.

George Brian Phillips, 60, has been a director or partner of the following companies or partnerships during the past five years:

Brian Phillips was a director of Valiant Sport Holdings Limited at the time it was placed into voluntary liquidation by members and creditors on 2 April 2013. The company was dissolved on 5 September 2014. There were no secured or preferential creditors. Unsecured creditors holding approximately £2.65m in aggregate received 0.7124p in pound.

Brian holds no shares in Tissue Regenix plc and there are no further disclosures required in accordance with AIM Rule 17 and Schedule Two paragraph (g) of the AIM Rules for Companies.